Sign in
4

Changes in Ownership

Contineum Therapeutics, Inc. Filed Acc 0001628280-26-047058

Chief Scientific Officer sold 37,179 shares at an average $15.99 ($594,578)

  • Chief Scientific Officer acquired 33,009 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I In the form
Lorrain Daniel S. Chief Scientific Officer 2026-06-30 Option exercise 10b5-1 +28,826 $1.01 $29,114 168,198 D
Lorrain Daniel S. Chief Scientific Officer 2026-06-30 Sale 10b5-1 −28,826 $16.04 $462,288 139,372 D
Lorrain Daniel S. Chief Scientific Officer 2026-07-01 Option exercise 10b5-1 +4,183 $1.01 $4,225 143,555 D
Lorrain Daniel S. Chief Scientific Officer 2026-07-01 Sale 10b5-1 −5,852 $15.67 $91,682 137,703 D
Lorrain Daniel S. Chief Scientific Officer 2026-07-01 Sale 10b5-1 −2,501 $16.24 $40,608 135,202 D
Derivatives
Lorrain Daniel S. Chief Scientific Officer 2026-06-30 Option exercise · Stock Option (right to buy) 10b5-1 −28,826 38,480 D
Lorrain Daniel S. Chief Scientific Officer 2026-07-01 Option exercise · Stock Option (right to buy) 10b5-1 −4,183 34,297 D
Open-market sales · 37,179 sh · avg $15.99 · $594,578
Loading xslF345X06/wk-form4_1783028831.xml…